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• The endothelium inhibits platelets via cyclic nucleotide dependent pathways. 
• cAMP and cGMP dependent protein kinases (PKA, PKG) inhibit the GTPase RhoA in 
platelets. 
• RhoA regulation does not involve phosphorylation of RhoA. 
• Phosphorylation of the RhoA regulators Myo9b and GEF-H1 mediates RhoA inhibition 











Circulating platelets are maintained in an inactive state by the endothelial lining of the 
vasculature. Endothelium-derived prostacyclin and nitric oxide stimulate cAMP- and cGMP-
dependent kinases, PKA and PKG, to inhibit platelets. PKA and PKG effects include the 
inhibition of the GTPase RhoA which has been suggested to involve the direct phosphorylation 
of RhoA on serine 188. 
 
Objectives 
We wanted to confirm RhoA S188 phosphorylation by cyclic nucleotide-dependent kinases 
and to identify possible alternative mechanisms of RhoA regulation in platelets. 
 
Methods 
Phosphoproteomics data of human platelets was used to identify candidate PKA and PKG 
substrates. Phosphorylation of individual proteins was studied by Western blotting and Phos-
tag gel electrophoresis in human platelets and transfected HEK293T cells. Pull-down assays 
were performed to analyse protein interaction and function.  
 
Results 
Our data indicate that RhoA is not phosphorylated by PKA in platelets. Instead, we provide 
evidence that cyclic nucleotide effects are mediated through the phosphorylation of the RhoA-
specific GTPase-activating protein Myo9b and the guanine nucleotide exchange factor GEF-
H1. We identify Myo9b S1354 and GEF-H1 S886 as PKA and PKG phosphorylation sites. 
Myo9b S1354 phosphorylation enhances its GAP function leading to reduced RhoA-GTP 
levels. GEF-H1 S886 phosphorylation stimulates binding of 14-3-3β and has been shown to 
inhibit GEF function by facilitating binding of GEF-H1 to microtubules. Microtubule 
disruption increases RhoA-GTP levels confirming the importance of GEF-H1 in platelets. 
 
Conclusion 
Phosphorylation of RhoA regulatory proteins Myo9b and GEF-H1, but not RhoA itself, is 
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Introduction 
Platelets play crucial roles in haemostasis, thrombosis and inflammation. In healthy, intact 
vasculature, the endothelial lining of blood vessels constantly releases prostacyclin (PGI2) and 
nitric oxide (NO). These factors contribute to the regulation of platelet function and 
haemostasis, by maintaining platelets in their inactive state (1-3). PGI2 binds to a Gs-coupled 
receptor thus stimulating cAMP synthesis by adenylate cyclase. NO diffuses through the 
cellular membrane and activates soluble guanylate cyclase (sGC) to produce cGMP. cAMP 
and cGMP activate cyclic nucleotide-dependent kinases, PKA and PKG, resulting in the 
phosphorylation of downstream substrate proteins. This ultimately causes the inhibition of 
platelet adhesion, aggregation and granule release. The list of potential PKA/PKG substrates 
in human platelets continues to expand (4), however, verification of substrates and 
understanding of functional consequences of phosphorylation events are still limited (1).  
The GTPase RhoA is a known target for regulation by cyclic nucleotide pathways. 
RhoA functions as a molecular switch by cycling between its active (RhoA-GTP) and inactive 
(RhoA-GDP) states which is controlled by GTPase activating proteins (GAPs) and guanine 
nucleotide exchange factors (GEFs). Various platelet agonists such as thrombin and 
thromboxane A2 have been shown to increase RhoA-GTP levels in human platelets (5-7) while 
cyclic nucleotide signalling inhibits RhoA activation (8). Megakaryocyte specific mouse 
knockout models indicate that RhoA is critical to platelet biology with RhoA depleted platelets 
showing reduced myosin light chain (MLC) phosphorylation, reduced integrin activation and 
impaired shape change in response to agonists (6, 9). The direct phosphorylation of RhoA on 
S188 by PKA/PKG has been proposed as a mechanism of RhoA inhibition (10). PKA mediated 
RhoA S188 phosphorylation was stipulated to inhibit membrane localisation of RhoA leading 
to MLC phosphatase activation, dephosphorylation of MLC and reduced stress fibre formation 
(11). Similar findings were obtained for PKG effects on RhoA in platelets (12, 13). 
Interestingly, NO-induced RhoA inhibition was described to be independent of RhoA S188 
phosphorylation (13). Recent phospho-proteome analyses of PKA/PKG signaling in human 
platelets provided no evidence for RhoA phosphorylation ((3, 4, 14) and SG, UW, OP, RPZ, 
KJ, unpublished). 
Alternative ways of regulating small GTPases might involve specific regulatory GAP 
or GEF proteins. We have previously shown that GAPs and GEFs of Rac1 (15), Gq and Gi (16), 
and Rap1B (17) are substrates for PKA/PKG phosphorylation in platelets. Little data on RhoA 
specific GAPs or GEFs in platelets is available so far (7, 18, 19). In this study we show that 
human platelets express Myo9b (unconventional myosin IXb), a myosin motor protein 
containing a RhoA specific GAP domain (20), and GEF-H1 (ARHGEF2), a microtubule 
regulated RhoA specific GEF (21). We provide evidence that PKA and PKG phosphorylate 
Myo9b and GEF-H1 in platelets leading to altered GAP and GEF functions that could 




cDNA constructs and site-directed mutagenesis 
Human eGFP-GEF-H1 construct has been described previously (22). FLAG-tagged human 
Myo9b was obtained from GenScript Biotech (OHu04432, Piscataway NJ, USA). eGFP-
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tagged human Myo9b was obtained by sub-cloning into eGFP-C1 using the Gibson assembly 
protocol© according to manufacturer’s protocol (E5510, New England Biolabs). eGFP-tagged 
rat Myo9b homologue was kindly provided by Martin Bähler (23). Glutathione-S-transferase-
(GST)-14-3-3β was prepared as described previously (17). GST-Rhotekin-Rho-binding-
domain (GST-RBD) was kindly provided by Harry Mellor (University of Bristol, UK). Point 
mutations were introduced into constructs by PCR using primers carrying the desired changes 
and PfuUltra High-fidelity DNA Polymerase (Agilent). WT plasmids were digested with DpnI 
restriction enzyme (Thermo Scientific) and mutants were grown in One Shot TOP10 
chemically competent E. coli (Thermo Fisher Scientific). Mutagenesis was confirmed by DNA 
sequencing (Eurofins Genomics).  
 
Antibodies 
Mouse anti-RhoA (sc-418, Santa Cruz Biotechnology), rabbit anti-phospho-RhoA (S188) 
(ab41435, Abcam, and orb335688, Biorbyt), rabbit anti-Rap1 (sc-65, Santa Cruz 
Biotechnology), rabbit anti-Rap1GAP2 (IG-1024, custom made by ImmunoGlobe),  rabbit 
anti-phospho-Rap1GAP2 (S7) (UDU-1-50-1, custom made by Epitomics/Abcam), rabbit anti-
Myo9b (12432-1-AP, Proteintech), rabbit anti-GEF-H1 (55B6, Cell Signaling Technology), 
rabbit anti-phospho-GEF-H1 (S886) (E1L6D, Cell Signaling Technology), rabbit anti-GFP 
(ab290, Abcam) were used as primary antibodies. For blots detected using enhanced 
chemiluminescence (ECL) method, horseradish peroxidase-coupled donkey anti-mouse, anti-
rabbit IgG (715–035-150, 711–035-152, Jackson ImmunoResearch Europe Ltd.) or donkey 
anti-goat IgG (sc2020, Santa Cruz Biotechnology) secondary antibodies were used. For blots 
detected using LI-COR Odyssey scanning system, IRDye 680LT goat anti-mouse IgG (926–
68020, LI-COR) and IRDye 800CW goat anti-rabbit IgG (926-3221, LI-COR) secondary 
antibodies were used. 
 
Cell culture and Platelet preparation 
HEK293T were cultured using Dulbecco's modified Eagle's medium including 10% foetal 
bovine serum and 1% penicillin/streptomycin (41965-039, 10270-106, 15070-063, Thermo 
Fischer Scientific) at 37 °C and 5% CO2 in air. Transient transfection was performed using 
PolyJet reagent (SL100688-05, SignaGen Laboratories) and cells were harvested on the 
following day. Primary platelets were obtained from healthy donors who had given their 
informed consent under the Declaration of Helsinki and with ethical approval from University 
College Dublin (LS-08-13-Smolenski, LS-19-68-Smolenski). 40 ml of venous blood was 
drawn into a 50 ml tube containing 10 ml of CCD-EGTA buffer (100 mM tri-sodium citrate, 7 
mM citric acid, 140 mM glucose, 15 mM EGTA). For Phos-tag analysis, 10 ml CCD-EGTA 
buffer was substituted with 8.4 ml of ACD buffer (85 mM tri-sodium citrate, 65 mM citric acid, 
100 mM glucose). Blood samples were aliquoted into 15 ml tubes (8 ml per tube) and 
centrifuged at 200 RCF at room temperature (RT; approx. 18°C) for 15 minutes without the 
brake. The upper platelet-rich plasma (PRP) layer was separated from other blood components 
and re-centrifuged at 600 RCF at RT for 10 minutes. Pelleted platelets were resuspended in 
prewarmed (37°C) platelet resuspension buffer (pH 7.4; 145 mM NaCl, 1mM MgCl2, 5 mM 
KCl, 10 mM glucose, 10 mM HEPES). Platelets were incubated at 37°C and ambient air for 
35-50 minutes before treatment and lysis. 
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Cell treatment and lysis 
HEK293T cells were incubated with 10 μM forskolin in DMEM for 10 min at 37°C and washed 
twice with chilled phosphate-buffered saline or, in case of Phos-tag analyses, with tris-buffered 
saline. Platelets were incubated in resuspension buffer with 0.5 µM or 50 nM PGE1 (P5515-
1MG, Sigma-Aldrich) for 30 seconds or 15 minutes, 10 µM forskolin (F6886-10MG; Sigma-
Aldrich) for 10 minutes, 10 µM SNP (31444-50G, Sigma-Aldrich) for 10 minutes, 0.1 U/ml 
thrombin (10602400001, Sigma-Aldrich) for 1 minute, 1 µM U46619 (16450, Cayman 
Chemical) for 1 minute or 10 µM nocodazole (SML 1665, Sigma-Aldrich) for 1 minute, all at 
37°C. 
Cells were lysed either in standard lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 5 
mM MgCl2, 1% Triton X-100) or, for RhoA-GTP assays, in Rap lysis buffer (200 mM NaCl, 
50 mm Tris-HCl (pH 7.4), 2.5 mM MgCl2, 10% (v/v) glycerol, 1% (v/v) Nonidet P-40) 
supplemented with Complete Mini EDTA Free protease inhibitor cocktail tablets 
(11836170001, Roche) and PHOSSTOP phosphatase inhibitor tablets (4906837001, Sigma-
Aldrich). For dephosphorylation experiments, lysate samples were treated with λ protein 
phosphatase as described in the manufacturer's protocol (P0753S, New England Biolabs). 
Lysed cell samples were centrifuged at 13,200 RPM at 4°C for 10 mins to remove cellular 
debris.  
 
Pull-down assays and immunoprecipitation 
Pull down assays of RhoA-GTP levels and 14-3-3 binding were performed using glutathione-
S-transferase (GST)-RBD and GST-14-3-3β fusion proteins. Fusion proteins were expressed 
in BL21 (DE3) E.coli (C2527H, New England Biolabs) and purified from bacterial lysates 
using GSH-4B resin (17075601, GE Healthcare). 10 μl of GST-RBD or GST-14-3-3β saturated 
GSH resin were added to cell lysates and incubated at 4°C for 1 hour (GST-RBD) or overnight 
(GST-14-3-3β). Resin was then washed using lysis buffer, PBS with 1% Triton X-100 and 
PBS. Immunoprecipitation of eGFP-tagged proteins was performed by adding 4 μl of GFP-
Trap_A beads (gta-20, Chromotek) to cell lysates and incubating for 1 hour at 4°C. Beads were 
then washed with lysis buffer, PBS with 1% Triton X-100 and PBS. For Phos-tag PAGE PBS 
was replaced by TBS in all wash buffers. All precipitated samples were boiled at 95°C with 
3XSDS sample buffer for SDS-PAGE or Phos-tag PAGE preparation. 
 
Phos-tag gel electrophoresis 
Phos-tag gel electrophoresis and blotting were performed as previously outlined (24). Specific 
gel running times and transfer times were optimised for individual proteins: RhoA and Rap1 
(run 2.5 hours 30 mA/gel; transfer 3 hours at constant 380 mA), Myo9b (run 16 hours 30 
mA/gel; transfer 6 hours at constant 380 mA). After transfer, traditional Western blotting 
protocols applied (24).  
 
Kinase assay 
In vitro phosphorylation assessment was performed using immunoprecipitated proteins, as 
described (15). Briefly, proteins were incubated with the catalytic subunit of PKA (P6000S, 
New England Biolabs) in the presence of 50 mM Tris/HCl pH 7.5, 10 mM MgCl2 and 50 
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μM cold ATP mixed with 1 μCi [γ-32P]ATP (BLU502A100UC, Perkin Elmer) at 30 °C for 90 
seconds. The reaction was stopped by addition of sample buffer and boiling and analyzed by 
SDS-PAGE and blotting followed by autoradiography. Blots were then analysed by Western 
blotting to verify total protein levels. 
 
Densitometry & Statistical analysis 
All Western blots analysed by ECL and x-ray film were exposed for the same length of time 
on one x-ray film for the same experiment, allowing detection of protein levels to be identical 
across, for example, IP and total protein levels, providing more accurate interpretations of 
changes in specific protein levels as ECL detection is semi-quantitative. ECL developed 
western blots were scanned as 600 dpi greyscale TIFF images using a CanoScan LiDE 90 
scanner (Canon, Tokyo, Japan). Densitometry was performed using ImageJ software (25) using 
whole lane boxed analysis. Western blots analysed using the LI-COR Odyssey scanning system 
are denoted in the respective figure legends and were analysed using Image Studio software 
(LI-COR). For platelet experiments ratios of band intensities were calculated and plotted. For 
transfected cells, calculated ratios were then normalized to controls (set to 1). All statistical 
analyses were performed using One-Way ANOVA and Bonferroni post-hoc test (Prism 6 




PKA/PKG-mediated RhoA regulation may not be due to direct phosphorylation 
The ability of cyclic nucleotide signalling to inhibit or reverse RhoA activation has been 
previously documented in platelet and endothelial cells ((8, 26) and supplementary Fig. 1A). 
RhoA has been described as the nexus of this mechanism, by being a direct target for PKA and 
PKG phosphorylation in platelets. This was shown by Western blotting using anti-phospho-
RhoA (pS188) antibodies (11, 13). We attempted to replicate these findings by analysing 
lysates of platelets treated with prostaglandin E1 (PGE1), an agonist of the PGI2 receptor, or 
forskolin, a direct activator of adenylate cyclase. Running samples on high-concentration 
acrylamide gels (13%) and blotting with anti-pS188-RhoA (Abcam) revealed three bands that 
increased in intensity in response to activation of cAMP signalling (Fig. 1A, right panel), 
however, none of these bands ran at the same level as RhoA (Fig. 1A, left panel). PKA 
activation in the samples was confirmed by detection of phosphorylated serine 7 of Rap1GAP2, 
an established PKA substrate in platelets (17). The absence of a phospho-RhoA band was 
confirmed using a second anti-phospho-RhoA antibody from a different manufacturer 
(Biorbyt, Supplementary Fig. 1B). These data suggested that currently available anti-pS188-
RhoA antibodies might either be unspecific or that RhoA might not be phosphorylated in 
human platelets. To test the ability of anti-pS188-RhoA antibodies to detect RhoA we 
overexpressed RhoA in HEK293T cells. Following forskolin treatment a faint band of 
phosphorylated RhoA could be detected (Supplementary Fig. 1C) suggesting that anti-pS188-
RhoA antibodies can detect RhoA. Therefore, to verify if RhoA is phosphorylated in platelets 
we employed Phos-tag gel electrophoresis, a method that does not require phospho-specific 
antibodies and that has been shown to enable phosphoprotein detection in human platelets 
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before (15, 16). In brief, the Phos-tag compound allows for efficient separation of 
phosphorylated and non-phosphorylated protein species which can be detected using total 
antibodies (24). Platelet-derived RhoA appeared as a single band with no evidence of a 
phosphorylation-induced band shift following PGE1 treatment (Fig. 1B). We observed a faint 
band above RhoA in untreated as well as PGE1 treated samples. To exclude that this band might 
represent phosphorylated RhoA we treated samples with λ protein phosphatase (λPP) before 
Phos-tag analysis to remove possible phosphate groups. λPP treatment did not alter band 
patterns confirming the absence of any RhoA phosphorylation. We also found platelet-derived 
RhoA appeared as a single band following forskolin treatment and SNP treatment 
(Supplementary Fig. 1D). To verify Phos-tag gels as an appropriate method for the analysis of 
small G-protein phosphorylation we assessed Rap1, an established substrate of PKA in platelets 
(27, 28). Phos-tag gel analysis of PGE1-treated platelets lead to the appearance of a shifted 
band confirming Rap1 phosphorylation in platelets (Fig. 1C). These data suggest that RhoA 
may not be phosphorylated directly by PKA or PKG in human platelets. 
 
PKA and PKG phosphorylate Myo9b S1354, enhancing Myo9b GAP activity 
To identify alternative mechanisms that could explain PKA/PKG-induced RhoA 
inhibition, we searched quantitative platelet phosphoproteomics data of human platelets treated 
with iloprost, a stable PGI2 analogue (4, 14), or riociguat, an sGC stimulator ((3) and SG, UW, 
OP, RPZ, KJ, unpublished), for candidate GAP and GEF proteins of RhoA. Of 20 
phosphorylated GAP proteins detected in platelets we excluded proteins not containing 
PKA/PKG consensus phosphorylation sites (R-R/K-x-pS/pT (29)) and not being RhoA specific 
according to the literature. This resulted in the identification of Myo9b as a candidate for 
PKA/PKG phosphorylation. To verify Myo9b as a PKA substrate, we first assessed 
phosphorylation in a cell free setting. eGFP-tagged Myo9b expressed in HEK293T cells and 
purified via GFP immunoprecipitation could be phosphorylated by the catalytic subunit of PKA 
(Fig. 2A and supplementary Fig. 2A). To test phosphorylation of endogenous Myo9b in intact 
platelets we used Phos-tag gels. In untreated platelets, Myo9b appeared as one band. Incubation 
with PGE1 or forskolin led to the appearance of a second band indicative of phosphorylation 
(Figs. 2B and 2C). We also observed a similar band shift in platelets treated with the NO donor 
SNP (Supplementary Fig. 2B). These data confirmed Myo9b as a substrate for PKA and PKG 
phosphorylation in human platelets. Interestingly, platelet activators thrombin and U46619 also 
induced a band shift (Fig. 2B, second and third lanes), suggestive of cAMP-independent 
phosphorylation of Myo9b.  
 Mass spectrometry studies in platelets ((3, 4, 14) and SG, UW, OP, RPZ, KJ, 
unpublished) suggested serine S1354 (-R-R-T-pS-F) of Myo9b as the main PKA/PKG 
phosphorylation site. Furthermore, Myo9b S1354 phosphorylation has been detected in other 
cell types as well (PhosphoSitePlus, (30)). S1354 matches the PKA/PKG consensus sequence 
and the site is conserved in many species including rat, mouse, dog, and pig as assessed by 
Clustal Omega alignment (31). To verify S1354 of Myo9b as target for PKA, we performed 
Phos-tag analysis of eGFP-tagged wildtype and S1354A mutant Myo9b expressed in 
HEK293T cells. Prior to lysis cells were treated with forskolin to activate endogenous PKA. 
Forskolin treatment induced a band shift of wildtype Myo9b (Fig. 2D, second lane p2) 
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compared to control (Fig. 2D, first lane p1). S1354A mutant Myo9b ran slightly lower than 
wildtype Myo9b suggesting a reduced degree of basal phosphorylation (Fig. 2D, third lane b). 
Importantly, S1354A mutation abolished the forskolin induced band shift (Fig. 2D, fourth lane 
b). These results confirm S1354 as a PKA phosphorylation site on Myo9b. The data also 
indicate that Myo9b might be phosphorylated on other residues that could be dependent on the 
presence of S1354. Indeed, treatment of lysates of Myo9b expressing cells with λPP prior to 
Phos-tag gel analysis lead to a downward shift of the Myo9b band below p1 (Supplementary 
Fig. 2C). 
To examine possible functional consequences of S1354 phosphorylation we measured 
the GAP activity of Myo9b towards endogenous RhoA using pull-down assays in HEK293T 
cells. In these experiments the rat ortholog was used which is 84% identical to human Myo9b 
at the protein level (including the S1354 (S1327 in rat) phosphorylation site (Supplementary 
Fig. 2D)). As shown in Fig. 2E both wildtype and SA mutant Myo9b expression led to a 
reduction in RhoA-GTP levels compared to controls. However, mutation of the PKA 
phosphorylation site of Myo9b caused a less pronounced inhibition of RhoA-GTP (Fig. 2F) 
suggesting that presence of the phospho-site is required for full GAP activity. These results 
confirm that Myo9b is a GAP of RhoA. Furthermore, the data indicate that PKA mediated 
phosphorylation may enhance the GAP activity of Myo9b.  
 
PKA and PKG phosphorylate GEF-H1 on S886 increasing 14-3-3 binding  
 Previous studies have indicated that cyclic nucleotide pathways can target both GAP as 
well as GEF proteins of small G-proteins like Rap1 and Rac1 (15, 17). Screening of platelet 
phospho-proteome data as described above revealed the RhoA-specific GEF GEF-H1 
(ARHGEF2) as another potential candidate for PKA/PKG phosphorylation. GEF-H1 has been 
shown to be phosphorylated by PKA on S886 (-R-R-R-pS-L-) in other cells before (32). In 
addition, previous data also suggested that phosphorylated S886 might be a binding site for the 
adapter protein 14-3-3 and 14-3-3 binding has been linked to GEF-H1 inhibition (32). To study 
the role of GEF-H1 and S886 phosphorylation in platelets, we performed pull-down assays 
using GST-14-3-3β in lysates of PGE1, forskolin or SNP treated platelets. A basal level of 
interaction between 14-3-3β and GEF-H1 could be detected in untreated platelets which 
increased following activation of PKA/PKG (Fig. 3A, upper panel). This increase in binding 
to 14-3-3β correlated with an increase in S886 phosphorylation (Fig. 3A, middle panel, and 
Fig. 3B). To further investigate a possible regulatory role of GEF-H1 and its phosphorylation 
in platelets we measured effects of known RhoA activators, thrombin and thromboxane A2 in 
platelets. Treatment of platelets with thrombin or the thromboxane receptor agonist U46619 
reduced GEF-H1/14-3-3β binding and did not induce S886 phosphorylation (Fig. 3C). GEF-
H1 is the only Rho-GEF known to be negatively regulated by microtubule binding (33-35). We 
therefore analysed effects of the microtubule-depolymerizing agent nocodazole on RhoA-GTP 
levels in platelets. Nocodazole treatment strongly increased RhoA-GTP levels compared to 
controls (Fig. 3D, E), confirming an important role of GEF-H1 for RhoA activation in platelets. 
The well-established ability of cyclic nucleotide pathways to inhibit RhoA-GTP formation 
correlated with GEF-H1 S886 phosphorylation and was not affected by nocodazole treatment 
(Fig. 3D, E). These results suggest that GEF-H1 might be another protein involved in the 
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inhibition of RhoA by cyclic nucleotide pathways in platelets in addition to Myo9b. GEF-H1 




Carefully controlled cycling of RhoA between active and inactive conformations 
represents a key signaling principle in many cells.  In the present study we describe Myo9b and 
GEF-H1 as novel RhoA regulators and targets for endothelium and cyclic nucleotide dependent 
RhoA inhibition in platelets (Fig. 4).  
RhoA phosphorylation at S188 has previously been suggested as a mechanism of RhoA 
regulation by cyclic nucleotides in different cell types including platelets  (10-13, 36, 37). 
Platelet experiments were based on standard immunoblotting methods using phospho-specific 
antibodies. However, our studies indicate that the detection of RhoA S188 phosphorylation 
with phospho-specific antibodies is not reliable and that the signals obtained might derive from 
other proteins. Using antibodies from two different suppliers we were not able to detect any 
evidence of RhoA phosphorylation after platelet treatment with comparable concentrations of 
cAMP/PKA agonists as described before (11, 13). Instead, antibodies cross-reacted with 
proteins of similar but not identical apparent molecular weight as RhoA. These bands could 
potentially have been mistaken for RhoA in previous studies due to the use of lower percentage 
SDS-PAA gels (10% in Atkinson et al. (13) compared to 13% in our study) which are less 
effective in resolving differences between small proteins. Unfortunately the phospho-RhoA 
S188 antibody used before ((11-13) from Santa Cruz Biotechnology) is no longer available and 
it cannot be ruled out that it might have been more specific compared to the Abcam and Biorbyt 
antibodies used here. Nonetheless we were able to confirm that the Abcam antibody (shown in 
Fig. 1A) is indeed able to detect overexpressed RhoA (Supplementary Fig. 1C). Of note, the 
constitutive posttranslational geranylgeranylation of RhoA at C190 required for cell membrane 
localization of RhoA has been shown to reduce the binding of phospho-RhoA S188 antibodies 
(10), which could contribute to detection problems. However, using Phos-tag gels, a method 
independent of phospho-specific antibodies, we were also not able to detect any RhoA 
phosphorylation in response to PKA activation in human platelets. As a positive control we 
used Rap1, which is a known more slowly phosphorylated PKA substrate (38). However, 
conditions that facilitated Rap1 phosphorylation did not induce RhoA phosphorylation. We 
conclude that direct S188 phosphorylation is unlikely to mediate PKA/PKG induced RhoA 
inhibition in platelets. Interestingly, endogenous RhoA phosphorylation could not be verified 
in studies of other cell types before. Bolz et al. reported that PKG-induced RhoA inhibition 
was independent of RhoA phosphorylation in resistance arteries (39), and Oishi et al. showed 
that RhoGDI phosphorylation was involved in PKA-mediated RhoA inhibition in cardiac 
fibroblasts instead of RhoA phosphorylation (40).  
Our study indicates that the RhoA GAP and GEF proteins Myo9b and GEF-H1 might 
be the actual PKA/PKG targets involved in RhoA inhibition. Both proteins have recently been 
confirmed to be RhoA specific (41). Myo9b is also a myosin motor protein that can move along 
actin filaments towards their plus-end (42). The motor domain is linked to a GAP domain 
which is thought to provide local control of RhoA at sites of actin polymerization (23). Myo9b 
has been implicated in lamellipodia formation and cell migration in macrophages, T-cells, and 
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epithelial cells (43-45). These Myo9b functions were associated with a regulation of RhoA-
GTP levels. Myo9b has not previously been described in platelets nor has its phosphorylation 
by cyclic nucleotide-dependent kinases. We mapped Myo9b phosphorylation to a highly 
conserved S1354 site localized between the N-terminal myosin motor and IQ or myosin light 
chain binding domains (aa146-953, aa957-1053) and the C-terminal GAP domain (aa1703-
1888). S1354 lies in the centre of a large uncharacterized region between amino acids 1100 to 
1500 scoring high for intrinsic protein disorder (46). Disordered regions are increasingly 
recognized as common targets for phosphorylation in many proteins (47). Our studies indicate 
that S1354 phosphorylation might enhance the GAP activity of Myo9b leading to reduced 
RhoA-GTP levels. Thus, Myo9b phosphorylation could contribute to local cyclic nucleotide-
mediated control of RhoA and the actin/myosin cytoskeleton in platelets. Previous studies of 
other small G-proteins like Rap1, Rac1, and Gq indicate that GAP regulation might be a 
common mechanism of cyclic nucleotide dependent control of platelets (15-17, 48, 49). We 
also observed agonist induced phosphorylation of Myo9b, suggestive of cAMP-independent 
PKA-mediated phosphorylation, previously proposed as an inhibitory feedback mechanism 
during thrombin- and collagen-induced platelet activation (50). 
 GEF-H1 has been shown to be expressed in platelets before (51) and it is known to 
regulate endomitosis of megakaryocytes (52). In the present study, we show that PKA and PKG 
phosphorylate GEF-H1 on S886 in human platelets leading to an increase in 14-3-3β 
interaction. PKA induced S886 phosphorylation has been described (32) and also other kinases 
like p21-activated kinase 1 or microtubule affinity-regulating kinase 2 (Par-1b) can 
phosphorylate S886 of GEF-H1 in cells other than platelets (34, 53). These studies have also 
indicated that S886 phosphorylation and 14-3-3 binding contribute to inhibition of GEF-H1 
activity, however, the phosphorylation of additional sites might be necessary for full GEF-H1 
inhibition (54). In contrast, dephosphorylation and loss of 14-3-3 might play a role in GEF-H1 
activation by thrombin (55). Our data support this concept showing that thrombin and 
thromboxane A2 reduce the interaction of GEF-H1 with 14-3-3. Thus 14-3-3 binding might 
constitute a switch used by cyclic nucleotide pathways to block GEF-H1 mediated RhoA 
activation, whereas platelet activators detach 14-3-3 from GEF-H1 to stimulate RhoA. A 
similar, although reverse, role of 14-3-3 has been described previously for RGS18, a GAP of 
Gq. Cyclic nucleotide inhibitory pathways detach 14-3-3 from RGS18 to activate it and to 
block Gq function, whereas platelet activators use 14-3-3 binding to stop RGS18 from turning 
off Gq signalling (1, 16, 48). The inactivation of GEF-H1 by 14-3-3 is linked to microtubule 
binding of the N-terminal domain of GEF-H1 (21) and GEF-H1 is the only GEF reported to 
localize at microtubules (35). Therefore, our finding that nocodazole-induced disruption of 
microtubules increases RhoA-GTP levels corroborate an important role for GEF-H1 in RhoA 
regulation in platelets. PKA-mediated GEF-H1 S886 phosphorylation and RhoA inhibition 
were not affected by the presence or absence of microtubules suggesting that cyclic nucleotide 
pathways might be able to inhibit GEF-H1 independent of its subcellular localisation.  
In conclusion we have identified new mechanisms of cyclic nucleotide dependent RhoA 
inhibition in platelets. Recently, Myo9b and GEF-H1 were shown to form a network with 
RhoA and actin filaments generating dynamic patterns of subcellular contractility (56). Initial 
experiments in our group indicate that Myo9b and GEF-H1 bind to each other independent of 
S1354 phosphorylation or microtubule integrity  (Supplementary Fig. 3B). It will be interesting 
RhoA regulation by Myo9b and GEF-H1 in platelets 
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to investigate how PKA and PKG mediated control of RhoA is coordinated at the level of 
Myo9b and GEF-H1 and ultimately at the wider level of the many hundred other substrates 
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FIGURE 1. RhoA may not be phosphorylated in human platelets. (A) Washed human platelets were 
incubated with or without PGE1 (50 nM, 30 sec) or forskolin (10 μM, 10 min) and lysed. SDS-PAGE 
was performed using 13% acrylamide gels followed by Western blotting and detection using the LI-
COR Odyssey scanning system. Membranes were cut, incubated with anti-RhoA or anti-RhoA pS188 
antibodies (as highlighted) and realigned for detection. Appearing bands representing RhoA and an 
unknown protein of higher molecular weight, detected by the anti-RhoA pS188 antibody, are indicated 
by arrows. RhoA and two unknown proteins detected by the anti-RhoA pS188 antibody are indicated 
by arrows. Rap1GAP2 S7 was used as a PKA phosphorylation control and detection was performed 
with a phospho-antibody against pS7 and a Rap1GAP2 total antibody. (B) Washed human platelets 
were incubated with or without PGE1 (0.5μM, 30 sec) and lysed. Platelet lysates were then incubated 
without or with λ protein phosphatase (λPP) for 60 min at 30oC. Aliquots of samples were subjected to 
Phos-tag PAGE followed by immunoblotting using an anti-RhoA antibody. A band of unknown identity 
above RhoA is indicated by an arrow. (C) Washed human platelets were incubated with or without 
PGE1 (0.5μM, 30 sec) and lysed. Aliquots of samples were subjected to Phos-tag PAGE followed by 
immunoblotting using an anti-Rap1 antibody and Western blotting and detection using the LI-COR 
Odyssey scanning system. Non-phosphorylated Rap1 and phosphorylated Rap1 (p-Rap1) are denoted 
by arrows. Data are representative of three independent experiments (A, B, C). 
 
 
FIGURE 2. Cyclic nucleotide-dependent kinases phosphorylate Myo9b on S1354, enhancing its 
GAP activity. (A) eGFP-Myo9b was expressed in HEK293T cells, immunoprecipitated and incubated 
with purified catalytic subunit of PKA (PKA-Cα) in the presence of [γ-32P]ATP for 90 sec. Samples 
were subjected to SDS PAGE and blotting. Radiolabelled Myo9b was detected by autoradiography 
(upper panel) and total Myo9b levels were determined using anti-GFP antibody (lower panel). This 
experiment was performed once. (B) Washed human platelets were incubated with or without thrombin 
(0.1 U/ml, 1 min), U46619 (1 μM, 1 min), PGE1 (0.5μM, 30 sec) or forskolin (10 μM, 10 min) and 
lysed. Aliquots of samples were analysed by Phos-tag PAGE followed by immunoblotting using an 
anti-Myo9b antibody. Basal (p1) and phosphorylated Myo9b (p2) are denoted by arrows. Data are 
representative of two (thrombin and U46619) or four (PGE1 and forskolin) independent experiments. 
(C) Blots of experiments shown in B (PGE1 and forskolin) were analysed by densitometry and the ratios 
of phosphorylated (p2) versus non-phosphorylated (p1) Myo9b were calculated. Data of four 
independent experiments are expressed as means ± SD. Statistical significance of differences between 
PGE1 and forskolin treatments and control was determined by One-Way ANOVA and Bonferroni post-
test (*p<0.01; **p<0.001). (D) HEK293T cells expressing Myo9b-WT or S1354A mutant were 
incubated without or with forskolin (10 μM, 10 min) and lysed. Aliquots of samples were subjected to 
Phos-tag PAGE followed by immunoblotting using anti-GFP antibody. Appearing Myo9b-WT bands 
were labelled as p1 (without forskolin) or p2 (with forskolin) and the trailing edge of the WT phospho-
bands are demarcated by dotted lines to highlight the PKA-induced band shift. The S1354A band is 
labelled as b. Data are representative of 4 independent experiments. (E) HEK293T cells were 
transfected with Myo9b WT or SA and endogenous levels of RhoA-GTP were analysed by pull-down 
assay followed by SDS-PAGE and Western blotting. Anti-RhoA antibody was used to determine RhoA-
GTP (upper panel) and total RhoA levels (middle panel) and anti-GFP antibody was used to determine 
total Myo9b levels (bottom panel). (F) Blots of experiments shown in A were analysed by densitometry 
and ratios of RhoA-GTP versus total RhoA were normalized to non-transfected controls (not shown). 
Data of five independent experiments are expressed as means ± SD. Statistical significance of relative 




FIGURE 3. GEF-H1 S886 phosphorylation by cyclic nucleotide-dependent kinases increases 14-
3-3 binding. (A) Washed human platelets were incubated with PGE1 (0.5 μM, 30 sec), forskolin (10 
μM, 10 min) or SNP (10 μM, 10 min), lysed and subjected to pull-down assays using GST-14-3-3β. As 
a control, a separate untreated platelet lysate was subjected to a pull-down assay using GST alone 
RhoA regulation by Myo9b and GEF-H1 in platelets 
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(Supplementary Fig. 3A). Precipitated, (14-3-3β bound, top panel), total (lower panel) and 
phosphorylated GEF-H1 (middle panel) were detected by Western blotting. (B) Blots of experiments 
shown in A were analysed by densitometry. Ratios of 14-3-3β bound versus total GEF-H1 and 
phosphorylated versus non-phosphorylated GEF-H1 were calculated. Data of four independent 
experiments are expressed as means ± SD. Statistical significance of differences between treatments 
and controls was determined by One-Way ANOVA and Bonferroni post-test (14-3-3β/GEF-H1 
interaction; *p<0.001, **p<0.0001).  (GEF-H1 S886 phosphorylation; #p<0.0001). (C) Washed 
human platelets were incubated with or without thrombin (0.1 U/ml, 1 min) or U46619 (1 μM, 1 min), 
lysed and subjected to pull-down assays using GST-14-3-3β. Precipitated, (14-3-3β bound, top panel), 
total (lower panel) and phosphorylated GEF-H1 (middle panel) were detected by Western blotting. Data 
representative of two independent experiments. (D) Washed human platelets were incubated with PGE1 
(0.5 μm, 30 sec) or nocodazole (10 μm, 1 min) or preincubated with PGE1 or nocodazole. For 
preincubated platelets, the order of treatment is indicated by +1 (added first) or +2 (added second). 
Platelets were lysed, and pull-down assays were performed using GST-RBD followed by Western 
blotting using anti-RhoA antibody to detect RhoA-GTP levels (top panel). Aliquots of platelet lysate 
were analysed using anti-RhoA (second panel), anti-GEF-H1 pS886 (third panel) and anti-GEF-H1 
(bottom panel). (E) Blots of experiments shown in C were analysed by densitometry. Ratios of RhoA-
GTP versus total RhoA and phosphorylated versus non-phosphorylated GEF-H1 were calculated. Data 
of three independent experiments are expressed as means ± SD. Statistical significance of differences 
between treatments and controls was determined by One-Way ANOVA and Bonferroni post-test. 
RhoA-GTP; control vs PGE1 (*p<0.001), control vs nocodazole (**p<0.0001), nocodazole vs 
PGE1/Noco and nocodazole vs Noco/PGE1 (#p<0.0001). 
 
 
FIGURE 4. Model of RhoA regulation by cyclic nucleotide-dependent protein kinases in human 
platelets.  Endothelium derived PGI2 and NO inhibit RhoA-GTP formation via stimulation of cyclic 
nucleotide signalling. PGI2 binds to the Gs-coupled IP receptor leading to adenylate cyclase (AC) 
stimulation, cAMP synthesis, and PKA activation. NO stimulates soluble guanylate cyclase (sGC), 
cGMP synthesis, and PKG activation. PKA and PKG phosphorylate the RhoA-specific GAP, Myo9b, 
at S1354 resulting in an increase in Myo9b GAP activity and reduction in RhoA-GTP levels. PKA and 
PKG also phosphorylate GEF-H1, a RhoA-specific GEF, at S886 leading to enhanced 14-3-3 
interaction and sequestration of GEF-H1 to platelet microtubules, resulting in a decrease in GEF-H1 
GEF activity contributing to a reduction in RhoA-GTP levels. Image created with BioRender.com.   
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Supplementary Figure 1. (Ai) Washed human platelets (approx. 1.5x108 platelets/500 μl aliquot) were 
pre-incubated without or with PGE1 (0.5 μm, 30 secs) or SNP (10 μm, 10 min) followed by U46619 (1 
μM, 1 min). Platelets were lysed and 20 μl of each lysate removed for analysis of total RhoA levels 
followed by GST-RBD pull down assays on the remaining lysate. Samples were then subjected to SDS-
PAGE/Western blotting. RhoA antibody was used to detect RhoA-GTP (upper panel) and total RhoA 
(lower panel) levels using ECL and X-ray film exposure. Data are representative of three independent 
experiments. (Aii) Western blots of experiments shown in (Ai) were analysed by densitometry and the 
ratios of RhoA-GTP versus total RhoA were calculated. Data are expressed as means ± SD. Statistical 
significance of the ratio of RhoA-GTP versus total RhoA was determined by ordinary One-Way 
ANOVA and Bonferroni post-test (U46619 vs U46619/SNP; **p < 0.001; U46619 vs U46619/PGE1; 
*p < 0.01) (U46619 vs control; #p <0.001). (B) Washed human platelets were treated with PGE1 
(0.5μM) for 30 seconds and then lysed. Lysates were then subjected to SDS-PAGE with a 13% 
acrylamide gel followed by Western blotting. Membranes were cut, incubated with anti-RhoA or anti-
RhoA pS188 (Biorbyt) antibodies (as highlighted) and realigned for detection. The RhoA band (approx. 
21 kDa) and a 15 kDa band detected by the anti-RhoA pS188 (Biorbyt) antibody are denoted by arrows. 
Data shown are representative of three independent experiments. (C) HEK293T cells expressing 3HA-
RhoA were incubated without or with forskolin (10 μM, 10 min) and lysed. Following SDS-PAGE, 
blots were subjected to immunoblotting with anti-RhoA pS188 (Abcam; upper panel) or anti-RhoA 
(lower panel) antibodies. Data shown are representative of three independent experiments. (D) Washed 
human platelets were incubated without or with PGE1 (0.5μM, 30 sec), forskolin (10 μM, 10 min) or 
SNP (10 μM, 10 min) and lysed. Aliquots of samples were subjected to Phos-tag PAGE followed by 




Supplementary Figure 2. (A) eGFP empty vector control or eGFP-Myo9b-WT were expressed in 
HEK293T cells, immunoprecipitated and incubated with purified catalytic subunit of PKA (PKA-Cα) 
in the presence of [γ-32P]ATP for 90 sec. Samples were subjected to SDS PAGE and blotting. 
Radiolabelled Myo9b was detected by autoradiography (upper panel) and total Myo9b levels were 
determined using anti-GFP antibody (lower panel). This experiment was performed once and is 
expanded to highlight the eGFP control for Fig. 2A. (B) Washed human platelets were incubated in the 
presence of SNP (10 μM, 10 min) and lysed. Lysates were incubated without or with λ protein 
phosphatase (λPP) for 60 min at 30oC. Aliquots of samples were analysed by Phos-tag PAGE followed 
by immunoblotting using an anti-Myo9b antibody with ECL and film detection. Non-PKG 
phosphorylated Myo9b (p1), phosphorylated Myo9b (p2) and dephosphorylated Myo9b (b) are denoted 
by arrows. Data are representative of 3 independent experiments. (C) HEK293T cells expressing eGFP-
Myo9b-WT were lysed and lysates were incubated without or with λ protein phosphatase (λPP) for 60 
min at 30oC. Aliquots of samples were subjected to Phos-tag PAGE followed by immunoblotting using 
anti-GFP antibody. Appearing eGFP-Myo9b-WT bands were labelled as p1 (without λPP) or b (with 
λPP). Data are representative of 4 independent experiments. (D) Alignment of Myo9b sequences from 
human and rat using Clustal Omega multiple sequence alignment. The highly conserved 
phosphorylation site (S1354 in human, S1327 in rat) is highlighted by the red box. This conserved 
region in human contains the RRTpSF sequence that conforms to the PKA/PKG consensus sequence 




Supplementary Figure 3. (A) Washed human platelets were lysed and subjected to pull-down assays 
using GST alone. Precipitated, (GST bound, top panel) and total (lower panel) GEF-H1 were detected 
by Western blotting using an anti-GEF-H1 antibody. (B) eGFP empty vector control, eGFP-Myo9b-
WT or eGFP-Myo9b-S1354A were expressed in HEK293T cells then incubated without or with 
forskolin (10 μM, 10 min) and lysed. Separately, eGFP-Myo9b-WT expressing cells were treated with 
nocodazole (10 μM, 10 min). eGFP-Myo9b-WT and eGFP-S1354A were immunoprecipitated followed 
by SDS-PAGE and Western blotting. Levels of endogenous GEF-H1 bound to eGFP-Myo9b were 
determined using an anti-GEFH1 antibody (top panel). Total eGFP-Myo9b (middle panel) and total 
endogenous GEF-H1 (bottom panel) levels were detected using anti-GFP and anti-GEF-H1 antibodies, 
respectively. Detection was performed using the LI-COR Odyssey scanning system. Shown are 
representative data of three independent experiments.  
